Amylyx Pharmaceuticals, Inc.2024财年第二财季实现净利润-72.70百万美元，同比减少429.41%

自选股智能写手08-18

8月18日，Amylyx Pharmaceuticals, Inc.（AMLX.US）公布财报，公告显示公司2024财年第二财季净利润为-72.70百万美元，同比减少429.41%；其中营业收入为-1.02百万美元，同比减少101.04%，每股基本收益为-1.07美元。从资产负债表来看，Amylyx Pharmaceuticals, Inc.（AMLX.US）总负债70.85百万美元，其中短期债务...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2460873658?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2024-08-18 00:04","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2460873658","market":"us","top_or_hot":-1,"title":"Amylyx Pharmaceuticals, Inc.2024财年第二财季实现净利润-72.70百万美元，同比减少429.41%","media":"自选股智能写手","content":"<div>\n<p>8月18日，Amylyx Pharmaceuticals, Inc.（AMLX.US）公布财报，公告显示公司2024财年第二财季净利润为-72.70百万美元，同比减少429.41%；其中营业收入为-1.02百万美元，同比减少101.04%，每股基本收益为-1.07美元。从资产负债表来看，Amylyx Pharmaceuticals, Inc.（AMLX.US）总负债70.85百万美元，其中短期债务...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408180006269f340746&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Amylyx Pharmaceuticals, Inc.2024财年第二财季实现净利润-72.70百万美元，同比减少429.41%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAmylyx Pharmaceuticals, Inc.2024财年第二财季实现净利润-72.70百万美元，同比减少429.41%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-08-18 00:04 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408180006269f340746&s=b><strong>自选股智能写手</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>8月18日，Amylyx Pharmaceuticals, Inc.（AMLX.US）公布财报，公告显示公司2024财年第二财季净利润为-72.70百万美元，同比减少429.41%；其中营业收入为-1.02百万美元，同比减少101.04%，每股基本收益为-1.07美元。从资产负债表来看，Amylyx Pharmaceuticals, Inc.（AMLX.US）总负债70.85百万美元，其中短期债务...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408180006269f340746&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AMLX","symbol_name":"Amylyx Pharmaceuticals, Inc.","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408180006269f340746&s=b","article_id":"2460873658","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408180006269f340746&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2460873658","pubTimestamp":1723910643,"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"8月18日，Amylyx Pharmaceuticals, Inc.公布财报，公告显示公司2024财年第二财季净利润为-72.70百万美元，同比减少429.41%；其中营业收入为-1.02百万美元，同比减少101.04%，每股基本收益为-1.07美元。从资产负债表来看，Amylyx Pharmaceuticals, Inc.总负债70.85百万美元，其中短期债务2.37百万美元，资产负债比为0.05，流动比率为0.05。机构评级：截至2024年8月18日，当前有6家机构对Amylyx Pharmaceuticals, Inc.目标价做出预测，其中目标均价为4.25美元，其中最低目标价为3.00美元，最高目标价为8.00美元。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":["earning"],"viewcount":null,"language":"zh","relate_stocks":{"AMLX":"Amylyx Pharmaceuticals, Inc."},"translate_title":"Amylyx Pharmaceuticals, Inc. achieved net profit of-US $72.70 million in the second fiscal quarter of fiscal 2024, a year-on-year decrease of 429.41%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AMLX":1},"content_text":"8月18日，Amylyx Pharmaceuticals, Inc.（AMLX.US）公布财报，公告显示公司2024财年第二财季净利润为-72.70百万美元，同比减少429.41%；其中营业收入为-1.02百万美元，同比减少101.04%，每股基本收益为-1.07美元。从资产负债表来看，Amylyx Pharmaceuticals, Inc.（AMLX.US）总负债70.85百万美元，其中短期债务2.37百万美元，资产负债比为0.05，流动比率为0.05。机构评级：截至2024年8月18日，当前有6家机构对Amylyx Pharmaceuticals, Inc.目标价做出预测，其中目标均价为4.25美元，其中最低目标价为3.00美元，最高目标价为8.00美元。公司简介：Amylyx Pharmaceuticals Inc是一家临床阶段的制药公司，致力于开发一种治疗肌萎缩性侧索硬化症和其他神经退行性疾病的新疗法。公司的唯一业务部门是研究和开发神经退行性疾病的治疗方法。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2460873658"}